| アブストラクト | INTRODUCTION: In Japan, real-world characterisation of cardiovascular disease (CVD) prevalence, incidence, and medication prescription in adults with type 2 diabetes (T2D) has been limited. METHODS: This real-world study (comprising a cross-sectional and a retrospective study) in adults aged >/= 20 years with T2D used the Medical Data Vision database to evaluate the prevalence and incidence of three-point major adverse cardiovascular events (3P-MACE) and composite CVD and to describe medication prescription patterns. RESULTS: The cross-sectional study included 292,383 patients in 2014 and 622,531 in 2021. Prevalence of 3P-MACE and composite CVD were 4.8% and 12.1%, respectively, in 2014; values in 2021 were 5.0% and 14.0%. In 2014, 2.1% of patients received glucagon-like peptide-1 receptor agonists (GLP-1RAs) and 0.8% received sodium-glucose cotransporter-2 inhibitors (SGLT-2is); 2021 values were 9.2% and 32.3%. The retrospective study included 314,206 patients; 19.7% had a CVD history. The overall incidence rate of 3P-MACE per 1000 person-years was 12.8 (95% confidence interval [CI] 12.6-13.0); 46.6 (45.3-48.0) in those with and 8.6 (8.4-8.8) in those without CVD history. The incidence rates (95% CI) of composite CVD were 47.9 (47.4-48.3); 179.5 (177.0-182.1) in those with and 31.5 (31.1-31.9) in those without CVD history. CONCLUSIONS: In Japan, the prevalence of 3P-MACE and composite CVD were almost unchanged from 2014 to 2021, whereas GLP-1RA/SGLT-2i prescriptions increased. Incidence rates of 3P-MACE and composite CVD were higher in patients with a CVD history. These data provide insights into prescription patterns in T2D in Japan and could inform future treatment practices. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13340-026-00877-7. |
|---|
| ジャーナル名 | Diabetology international |
|---|
| Pubmed追加日 | 2026/3/19 |
|---|
| 投稿者 | Komatsu, Mitsuhisa; Kobayashi, Hiroshi; Tsuboi, Satoshi; Watada, Hirotaka |
|---|
| 組織名 | Division of Diabetes, Endocrinology and Metabolism, Department of Internal;Medicine, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto, Nagano;390-8621 Japan. ROR: https://ror.org/05b7rex33. GRID: grid.444226.2. ISNI: 0000;0004 0373 4173;Cardiovascular and Emerging Therapy Areas, Medical Affairs Department, CMRQ;Development Division, Novo Nordisk Pharma Ltd, Tokyo, Japan. GRID: grid.518702.9;RWE Group, SPVD Department, CMRQ Development Division, Novo Nordisk Pharma Ltd,;Tokyo, Japan. GRID: grid.518702.9;Department of Metabolism and Endocrinology, Juntendo University Graduate School;of Medicine, Tokyo, Japan. ROR: https://ror.org/01692sz90. GRID: grid.258269.2.;ISNI: 0000 0004 1762 2738 |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41852486/ |
|---|
